HONG KONG, Feb. 12, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION-30/AK104-309) for its independently developed...
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC )
Also on site :
- Ministry of Economy Establishes the Syrian-Canadian Business Council
- Today’s NYT ‘Strands’ Hints, Spangram and Answers for Friday, July 4
- Beloved ‘60s Icon, 75, Dazzles London Event in Chic Pink Blazer and High-Top Sneakers